Sirion Holdings, Inc. 4
4 · Sirion Holdings, Inc. · Filed Dec 26, 2006
Insider Transaction Report
Form 4
Avalon Ventures VI LP
10% Owner
Transactions
- Other
Common Stock
2006-12-21+38,517→ 1,059,467 total
Footnotes (2)
- [F1]The shares of Common Stock listed in Table I were acquired by the reporting person as contingent consideration in exchange for stock of Sytera, Inc. ("Sytera") pursuant to the merger of Sytera into Sirion Therapeutics, Inc., a wholly owned subsidiary of the issuer ("Sirion Therapeutics"), as a result of the occurrence of events with respect to the development of the proprietary drug compound designated ST-602, which Sirion Therapeutics acquired as a result of the merger. In connection with the issuer's acquisition of Sirion Therapeutics, the issuer assumed Sirion Therapeutics' obligations to pay the contingent consideration owed to the former stockholders of Sytera as a result of the merger. The reporting person may receive an indeterminate number of additional shares of Common Stock as additional contingent consideration pursuant to the merger based on the occurrence, if any, of additional events with respect to the development and commercialization of ST-602.
- [F2]See Footnote 1.